Core Viewpoint - Jichuan Pharmaceutical has signed an exclusive commercialization rights agreement with Shanghai Zedeman Pharmaceutical Technology, allowing Jichuan to exclusively commercialize Zedeman's product, Zeli Mei (Bimekizumab) cream, in mainland China [1] Group 1: Agreement Details - The agreement involves a total payment of up to 190 million yuan (including tax) for upfront and milestone payments [1] - Zeli Mei is the first approved aromatase receptor modulator for the treatment of eczema in children aged 2 and above, as well as adults [1] Group 2: Market Potential - The drug has not yet been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory and is currently in the early stages of market expansion [1] - The market for atopic dermatitis drugs in China is projected to grow from 11 billion yuan in 2024 to 29.7 billion yuan by 2028 [1] Group 3: Strategic Implications - This transaction will enhance the company's product line and contribute to sustainable development, positively impacting future profitability and performance growth [1]

Core Insights - The market demand for eczema treatments is evolving, with a shift towards non-hormonal innovative drugs like Zhilimei (Bimekizumab), which are gaining traction due to their efficacy and safety profile [1][2][5] Group 1: Market Trends - There is a notable trend of "consumerization" in the pharmaceutical sector, where patients are increasingly involved in treatment decisions, prioritizing safety and brand reputation [6][7] - The demand for non-hormonal treatments is rising as traditional hormonal therapies face limitations due to side effects and patient fears [1][6] Group 2: Product Overview - Zhilimei is the first innovative drug approved for treating eczema in children over two years old, utilizing a novel mechanism targeting the aryl hydrocarbon receptor (AhR) [2][4] - Clinical trials indicate that nearly 60% of patients experience significant itch relief after eight weeks of treatment, with over 80% efficacy in children [2][3] Group 3: Clinical Validation - The 2025 Expert Consensus on Eczema Treatment in China highlights Zhilimei as a key treatment option, emphasizing its dual benefits of inflammation suppression and skin barrier repair [2][4] - Real-world patient feedback shows significant improvements in symptoms, with over 73% of children experiencing resolution of eczema symptoms after using Zhilimei [3][5] Group 4: Sales and Market Performance - Zhilimei achieved significant sales growth, with a 500% increase in transaction volume during the recent Double 11 shopping festival on JD.com [6][7] - The product has been recognized in the 2025 Shanghai Biopharmaceutical "New and Excellent Drug" directory, reflecting its acceptance across various stakeholders [7]